/PRNewswire/ Exact Sciences Corp. (Nasdaq: EXAS) today announced that the company generated revenue of $456.4 million for the third quarter ended September.
/PRNewswire/ Exact Sciences Corp. (Nasdaq: EXAS) today announced that company management will participate in the following conferences and invited investors.
/PRNewswire/ Exact Sciences Corp. (NASDAQ: EXAS) today shared data from modeling analyses that demonstrate Cologuard (mt-sDNA), with its included patient.
New Cologuard® Modeling Data Show Patient Navigation Matters When Reaching Underserved Populations for Colorectal Cancer (CRC) Screening streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ Exact Sciences Corp. (NASDAQ: EXAS) today shared data from modeling analyses that demonstrate Cologuard (mt-sDNA), with its included patient.